>
Switch to:

Allergy Therapeutics Cash Flow from Operations

: $11.0 Mil (TTM As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Jun. 2021, Allergy Therapeutics's Net Income From Continuing Operations was $-16.7 Mil. Its Depreciation, Depletion and Amortization was $2.9 Mil. Its Change In Working Capital was $7.9 Mil. Its cash flow from deferred tax was $0.0 Mil. Its Cash from Discontinued Operating Activities was $0.0 Mil. Its Asset Impairment Charge was $0.0 Mil. Its Stock Based Compensation was $0.8 Mil. And its Cash Flow from Others was $-1.0 Mil. In all, Allergy Therapeutics's Cash Flow from Operations for the six months ended in Jun. 2021 was $-6.2 Mil.


Allergy Therapeutics Cash Flow from Operations Historical Data

The historical data trend for Allergy Therapeutics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Cash Flow from Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 -5.06 7.10 15.63 11.78

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.80 19.12 -2.63 17.19 -6.15

Allergy Therapeutics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Allergy Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2021 is calculated as:

Allergy Therapeutics's Cash Flow from Operations for the quarter that ended in Jun. 2021 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was $11.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Allergy Therapeutics's net income from continuing operations for the six months ended in Jun. 2021 was $-16.7 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Allergy Therapeutics's depreciation, depletion and amortization for the six months ended in Jun. 2021 was $2.9 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Allergy Therapeutics's change in working capital for the six months ended in Jun. 2021 was $7.9 Mil. It means Allergy Therapeutics's working capital increased by $7.9 Mil from Dec. 2020 to Jun. 2021 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Allergy Therapeutics's cash flow from deferred tax for the six months ended in Jun. 2021 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Allergy Therapeutics's cash from discontinued operating Activities for the six months ended in Jun. 2021 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Allergy Therapeutics's asset impairment charge for the six months ended in Jun. 2021 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Allergy Therapeutics's stock based compensation for the six months ended in Jun. 2021 was $0.8 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Allergy Therapeutics's cash flow from others for the six months ended in Jun. 2021 was $-1.0 Mil.


Allergy Therapeutics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)